{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-060256","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2023-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.114582+00:00","generated_at":"2026-06-13T00:22:33.525934+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroOne raises ~$5.2M net in registered direct offering of 6M shares at $1.00/share","bullets":["Offered and sold 6,037,500 shares (including full overallotment) at $1.00 per share raising gross ~$6.04M.","Net proceeds of ~$5.215M after underwriting discounts and offering expenses.","Proceeds to fund EVO sEEG commercial launch with Zimmer Biomet, FDA filing for OneRF ablation, and drug-delivery electrode design.","Offering closed July 27, 2023; 90-day lock-up for insiders on further share sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-060256","json":"https://secwatch.observer/filing/0001213900-23-060256.json","markdown":"https://secwatch.observer/filing/0001213900-23-060256.md","text":"https://secwatch.observer/filing/0001213900-23-060256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023060256/0001213900-23-060256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023060256/ea182399-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T00:22:33.525934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e0ca2293ff393cf9e6cf8846ffe78ae34a96b2c7","claim":"NEUROONE MEDICAL TECHNOLOGIES Corp entered into Underwriting Agreement with The Benchmark Company, LLC valued at approximately $5,214,875 (effective 2023-07-24).","evidence_excerpt":"On July 24, 2023, NeuroOne Medical Technologies Corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with The Benchmark Company, LLC, as underwriter (the “Underwriter”), relating to the issuance and sale of 5,250,000 shares of the Company’s common stock, par value $0.001 per share, at a price to the public of $1.00 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1500198/000121390023060256/0001213900-23-060256-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"The Benchmark Company, LLC"},{"label":"Value","value":"approximately $5,214,875"},{"label":"Effective","value":"2023-07-24"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}